Trial

Activated protein C is an endogenous modulator with antithrombotic, anti-inflammatory and profibrinolytic properties. Underexpression of activated protein C plays a role in the progression of sepsis. Drotrecogin (Xigris®) is recombinate

One Two Three Four Number of Dysfunctional Organs

Figure 7.1. Mortality is directly associated with the number organ failures.

activated protein C that reduces inflammation, coagulation and increased fibrinolysis. The PROWESS trial evaluated the use of drotrecogin alfa in severe sepsis and found an improved survival at 28 days. Mortality was 24.7% in drotrecogin alfa treatment groups versus 30.8% in control groups. Patients at the highest rick (APACHE > 25) had the greatest benefit with a 13% reduction in mortality. Those patients with APACHE < 20 had the lease benefit. Bleeding complications with the use of drotrecogin alfa are 17% versus 8% in placebo groups.

Current dosing for Xigris is 24 ^g/kg/hour over 4 days. In a recent symposium, patients with significant improvement the infusion was stopped early without any significant loss of benefit. This drug is expensive with a cost of infusion at $6600.00. The end result is 18 patients must be treated to save one life with Xigris.

How To Win Your War Against Back Pain

How To Win Your War Against Back Pain

Knowing the causes of back pain is winning half the battle against it. The 127-page eBook, How To Win Your War Against Back Pain, explains the various causes of back pain in a simple manner and teaches you the various treatment options available. The book is a great pain reliever in itself. The sensible, practical tips that it presents will surely help you bid good-bye to back pain forever.

Get My Free Ebook


Post a comment